IDH1 and acute myeloid leukemia: Experimental observations collected in vitro, where IDH2 mutants can block the differentiation of HSPCs (26, 28, 29) and in vivo suggest that IDH1/IDH2 mutations act as canonical class II mutations, required to cooperate with class I mutations to promote AML.